Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis

pemvidutide (ALT-801) - Altimmune

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYBDTkx6bcmO0xWBwpqsWC76wOJb8ReVu-lxauMXRECiL0

Naim Alkhouri1; Mazen Noureddin2; Shaheen Tomah3; Julio Gutierrez3; John Suschak3; M. Scot Roberts3; Rachel Garner3; Sarah Browne3; M. Scott Harris3; Christophe Arbet-Engels3

Mar 18, 2026